Another study by Lim et al. (2017) in non-small cell lung cancer (NSCLC) also identified a 29-gene classifier of tumor matrisome (here on out referred to as COL11A1-matrisome signature) that predicts poor clinical outcome and drug resistance in patients where COL11A1 is the top upregulated protein [43,44]. Here, COL11A1 is linked to neoplasm.